1 / 3

COVID-19 Impact on Global Xerostomia Therapeutics Market

As per the research conducted by GME, the Xerostomia Therapeutics Market will grow with a CAGR value of 3.8 percent by 2026. <br>Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on u201cXerostomia Therapeutics Market - Forecast to 2026" <br>https://www.globalmarketestimates.com/market-report/global-xerostomia-therapeutics-market-3140<br>

gmeglobalmarket
Download Presentation

COVID-19 Impact on Global Xerostomia Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Xerostomia Therapeutics Market Size - Forecasts to 2026 As per the research conducted by GME, the Xerostomia Therapeutics Market will grow with a CAGR value of 3.8 percent by 2026. Factors boosting demand growth include increasing prescription drug consumption, quick accessibility & cost-effectiveness of drugs, a rising elderly population demographic, and an uptick in the incidence of disorders such as Sjogren's syndrome, HIV, diabetes, and Alzheimer's disease, among others. Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Xerostomia Therapeutics Market - Forecast to 2026" https://www.globalmarketestimates.com/market-report/global-xerostomia-therapeutics-market-3140 By Product (Salivary Stimulants, Salivary Substitutes, and Dentifrices), By Type (OTC and Prescription),By Region (North America, Asia Pacific, CSA, Europe, and The Middle East and Africa); End-User Landscape, Company Market Share Analysis, and Competitor Analysis Key Market Insights The expanded utilization of radiation therapy and chemotherapy is foreseen to boost the prevalence of xerostomia, which is assumed to fuel the xerostomia therapeutics market. Dentifrices areforeseen to lead in the product segment because it efficiently eliminates tooth decay, and those drugs contain low fluoride concentrations that are favoured by core patients. OTC is likely to lead in the type segment because they offer acute relief and have fewer adverse effects than traditional opioid medications. North America is presumed to dominate this market because of the surge in the volume of campaigns for promoting consciousness and assisting patients with xerostomia. GlaxoSmithKline PLC, Church & Dwight Co., Inc., Colgate-Palmolive Company, Hikma Pharmaceuticals PLC, Pendopharm, Sun Pharmaceuticals Industries Ltd., Lupin Pharmaceuticals, Inc., Pfizer, Inc., Parnell Pharmaceuticals, Inc., Acacia Pharma, and OraCoat are the major players in the xerostomia therapeutics market. Browse the Report @ https://www.globalmarketestimates.com/market-report/global-xerostomia- therapeutics-market-3140 Product Type Outlook (Revenue, USD Billion, 2021-2026)

  2. Salivary Stimulants Salivary Substitutes Dentifrices Type Outlook (Revenue, USD Billion, 2021-2026) OTC Prescription Regional Outlook (Revenue, USD Billion, 2021-2026) North America The U.S. Canada Mexico Europe Germany UK France Spain Italy Rest of Europe Asia Pacific China India Japan South Korea Australia Rest of APAC Central & South America Brazil Argentina Rest of CSA Middle East & Africa

  3. Saudi Arabia UAE Rest of MEA Contact: Tracy Simon Email address: tracy.simon@globalmarketestimates.com Phone Number: +16026667238 Website: https://www.globalmarketestimates.com/ Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php

More Related